{"brief_title": "Registry of Etanercept (Enbrel\u00ae) In Children With Juvenile Rheumatoid Arthritis", "brief_summary": "This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.", "condition": ["Juvenile Rheumatoid Arthritis"], "intervention_type": ["Drug"], "intervention_name": ["Enbrel\u00ae"], "description": ["Etanercept alone, etanercept plus methotrexate or other DMARDs"], "arm_group_label": ["Methotrexate group"], "study_pop": "\n      ", "sampling_method": "Non-Probability Sample", "criteria": "- JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry - Polyarticular or systemic RA in 3 or more joints at start of treatment", "gender": "All", "minimum_age": "2 Years", "maximum_age": "18 Years", "healthy_volunteers": "No", "keyword": "Registry", "mesh_term": ["Arthritis", "Arthritis, Rheumatoid", "Arthritis, Juvenile", "Methotrexate", "Etanercept"], "id": "NCT00078793"}